Reportlinker Adds Blood-Brain Barrier Technologies and Global Markets
NEW YORK, May 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Blood-Brain Barrier Technologies and Global Markets
REPORT HIGHLIGHTS
*
The global market for blood-brain barrier (BBB) technology for therapeutics amounted to $12.3 million in 2010 and will reach $387 million by 2015, a compound annual growth rate (CAGR) of 99.3%.
*
The most common means of BBB passage or type of technology will be receptor-mediated transport (RMT), meaning crossing the BBB via certain receptors that include the insulin or transferrin receptors. This technology was valued at $12 million in 2010 and is expected to increase at a nearly 99% compound annual growth rate (CAGR) to reach $376 million in 2015.
*
The other technology to emerge as a vehicle for taking a drug across the BBB that otherwise could not cross it is carrier-mediated transport. This sector was valued at $0.2 million in 2010 and is expected to increase at a 121% compound annual growth rate (CAGR) to reach $10.5 million in 2015.
INTRODUCTION
STUDY GOALS AND OBJECTIVES
BCC's goal in conducting this study was to determine the current status of the global therapeutic market for blood-brain barrier (BBB) technologies, including its growth potential over a 5-year period from 2010 to 2015. Our key objective was to present a comprehensive analysis of the current BBB technology and drug development market and its future direction with the aim to first define and classify that technology as it pertains to therapeutics in which the technology enables the therapeutic to directly cross rather than bypass the BBB.
REASONS FOR DOING THIS STUDY
BBB technologies are going to open up a vast untapped potential in the growing central nervous system therapeutic market where today growth is limited by the complexity of this layer in the brain that prevents the passage of many potentially useful molecules/compounds.
This report offers a picture of this technology potential that is on the verge of rapid increase. Therapeutics make up the main area of investment related to this technology; and, therefore, that is this report's focus. BCC has not yet examined the BBB, although the central nervous system has been a consistent focus. As such, this snapshot and study of trending and growth is unique.
SCOPE OF REPORT
The scope of this study encompasses companies that develop technologies to enable the crossing of the BBB and drug development in which a quality of the development is enabling the crossing of the BBB in cases in which passage was previously impossible often due to size. BCC analyzes each technology, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next 5 years. Technological issues, including the latest trends, are discussed.
INTENDED AUDIENCE
In the report, BBB technology is described in terms of what it is and its history in medicine, the types and technology categories, major companies, impact on the pharmaceutical market, applications, current market values, growth potential, and significant trends. This study will be of interest to the biotechnology and pharmaceutical industries and related life science, analytics, drug discovery, and diagnostic test manufacturing companies as well as all those interested or actively working in drug and imaging agent research and investors in all of the above.
METHODOLOGY
BCC presents an analysis of the types of technologies, applications, and therapeutic areas representing financial value in the area of BBB technology in medicine as it relates primarily to drug discovery, development, and commercialization. Estimated values are based on actual aggregate sales for the years discussed. Information, in general, is compiled through a combination of primary and secondary research, including annual reports and interviews with company officials.
INFORMATION SOURCES
BCC's analysis includes the review of more than 50 companies and information from financial and trade publications as well as the U.S. Food and Drug Administration. Included were pharmaceutical and biotechnology companies as well as support companies to them.
CHAPTER ONE: INTRODUCTION 1
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THIS STUDY 1
SCOPE OF REPORT 1
INTENDED AUDIENCE 2
METHODOLOGY 2
INFORMATION SOURCES 2
ABOUT THE AUTHOR 2
RELATED BCC REPORTS 2
BCC ONLINE SERVICES 3
DISCLAIMER 3
CHAPTER TWO: EXECUTIVE SUMMARY 4
EXECUTIVE SUMMARY 4
EXECUTIVE SUMMARY (CONTINUED) 5
EXECUTIVE SUMMARY (CONTINUED) 6
EMERGING BBB TECHNOLOGY MARKET 7
EMERGING BBB TECHNOLOGY MARKET (CONTINUED) 8
KEY DRIVERS 9
KEY CHALLENGES 10
MAJOR TRENDS 11
SUMMARY TABLE GLOBAL MARKET FOR BBB TECHNOLOGY FOR
THERAPEUTICS, THROUGH 2015 ($ MILLIONS) 12
SUMMARY FIGURE GLOBAL MARKET FOR BBB TECHNOLOGY FOR
THERAPEUTICS, THROUGH 2015 ($ MILLIONS) 12
CHAPTER THREE: OVERVIEW 13
TODAY'S PHARMA MARKET 13
FIGURE 1 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL
DRUGS, BY REGION, 2009 AND 2015 (PERCENT OF GLOBAL
SALES) 14
FIGURE 2 EMERGING MARKETS' GROWTH IN PHARMACEUTICAL
SALES, 2015 (ESTIMATED $ BILLIONS) 15
TODAY'S PHARMA MARKET (CONTINUED) 16
FIGURE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR
THERAPEUTICS, BY REGION, 2015* ($ MILLIONS) 17
BIOLOGICS 18
FIGURE 4 INVESTMENT IN BIOLOGICS AS A PERCENTAGE OF
TOTAL R&D, 2009 (PERCENT OF TOTAL R&D) 18
BIOLOGICS (CONTINUED) 19
GENERICS SIGNAL NEED FOR INNOVATION 20
NEUROFOCUSING IN THE PHARMA INDUSTRY 20
FIGURE 5 CNS REVENUE DISTRIBUTION BY DISEASE TARGET,
2009 ($ BILLIONS) 21
FIGURE 5 (CONTINUED) 22
FIGURE 6 GLOBAL MARKET FOR BBB TECHNOLOGY FOR
THERAPEUTICS, 2015 AND 2017 (NUMBER OF UNITS) 22
FIGURE 6 (CONTINUED) 23
FIGURE 7 GLOBAL MARKET FOR BBB TECHNOLOGY FOR
THERAPEUTICS, BY INDICATION, 2015 AND 2017 (NUMBER OF
UNITS PER INDICATION) 23
FIGURE 7 (CONTINUED) 24
NEUROFOCUSING IN THE PHARMA … (CONTINUED) 25
TABLE 1 TOP PHARMA COMPANIES BY REVENUE, 2009 ($
BILLIONS) 26
EMERGING BBB TECHNOLOGY MARKET 26
BRIEF HISTORY OF BBB 27
BLOOD BRAIN BARRIER DEFINED 28
BBB COMPONENTS 29
FIGURE 8 PARTS OF THE BBB 30
BBB ILLUSTRATED 30
MAIN AREAS OF THE BRAIN 31
FIGURE 9 THE BRAIN: BBB PROTECTS AND BRIDGES IT TO
BLOOD VESSELS 31
TREATING DISEASE AND THE BBB 32
MENINGITIS 33
MULTIPLE SCLEROSIS (MS) 33
ENCEPHALITIS 34
ALZHEIMER'S DISEASE (AD) 34
PARKINSON'S DISEASE (PD) 35
BBB TECHNOLOGY CLASSIFICATION 36
MOST COMMON BBB TECHNOLOGY 37
CHALLENGES WITH THE MOST COMMON TECHNOLOGY
USED 38
TRANSPORT CONSIDERATIONS 39
BYPASSING THE BBB 39
BBB TECHNOLOGY DETAILED 40
CHEMICAL TRANSPORT SYSTEMS 40
BIOLOGICAL CARRIER OR TRANSPORT SYSTEMS 40
PHYSICAL FORCE (ENERGETIC) OPENING THROUGH
SOUND WAVES (TARGETED ULTRASOUND) 41
Physical Force (Energetic) Opening…(Continued) 42
FIGURE 10 METHODS OF CROSSING THE BBB 43
ENHANCING BIOLOGICAL TRANSPORT SYSTEM TECHNIQUES 44
NANOPARTICLES AND LIPOSOMES 44
NANOPARTICLES 44
TABLE 2 DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB
TECHNOLOGY 45
Challenges with Nanoparticles 46
Liposomes 47
Liposomes (Continued) 48
PATENTS AND INTELLECTUAL PROTECTION 49
TABLE 3 KEY BBB TECHNOLOGY PATENTS 49
PATENTS AND INTELLECTUAL (CONTINUED) 50
ARMAGEN'S PATENT ESTATE 51
ArmaGen's Patent Estate (Continued) 52
LIFE AFTER PATENTING 53
TABLE 4 SAMPLE OF 2010 FINANCIAL DEALS IN CNS
THERAPEUTICS 54
BBB TECHNOLOGY MARKET: PRESENT AND FUTURE 55
TABLE 5 SAMPLE OF 2010 FINANCIAL DEALS IN BBB
TECHNOLOGY RECEIVED THROUGH PHARMACEUTICAL
COMPANY (ESTIMATED, $ MILLIONS) 55
FIGURE 11 COMPOSITION OF BBB TECHNOLOGY INDUSTRY BY
TECHNOLOGY TYPE IN THE DEVELOPMENT PIPELINE, 2010*
(%) 56
FIGURE 12 COMPOSITION OF BBB TECHNOLOGY BY
TECHNOLOGY TYPE IN THE COMMERCIALIZED (THERAPEUTIC
DRUG) MARKET, 2015 (%) 57
BBB TECHNOLOGY MARKET:… (CONTINUED) 58
FIGURE 13 DRUGS IN DEVELOPMENT USING BBB-PASSAGE
TECHNOLOGY, 2010 AND 2015 (NUMBER OF UNITS) 59
TABLE 6 BBB TECHOLOGY COMPANIES AND RESPECTIVE
TECHNOLOGICAL METHODOLOGY 60
TABLE 7 BBB TECHOLOGY COMPANIES AND CORPORATE
PARTNERS/LICENSING DEAL WITH LEAD DISEASE TARGET 61
GENZYME INNOVATES IN-HOUSE 61
DRUG DEVELOPMENT IN THE CNS 62
MULTIPLE MODELS MUST BE USED 63
BBB IS ITS OWN SITE OF INVESTIGATION 63
BBB is its Own Site of Investigation (Continued) 64
UNDERSTANDING INTERACTIONS AND BRAIN AREAS AS
DISTINCT 65
TABLE 8 SUCCESS FACTORS IN CNS DRUG DEVELOPMENT USING
BBB TECHNOLOGIES 66
TABLE 8 (CONTINUED) 67
WHAT VALUES ARE BEST? 67
TABLE 9 FREQUENT DRUG DEVELOPMENT CHALLENGES AND
THEIR CLINICAL EFFECTS 68
PROMISING RESEARCH 69
PROMISING RESEARCH (CONTINUED) 70
PROMISING RESEARCH (CONTINUED) 71
PROMISING RESEARCH (CONTINUED) 72
PROMISING CNS DRUGS IN THE PIPELINE FOR POTENTIAL
USE WITH BBB TECHNOLOGY 73
BRAIN CANCER 74
TABLE 10 GLOBAL PIPELINE FOR BRAIN CANCER, THROUGH 2015 74
TABLE 10 (CONTINUED) 75
TABLE 10 (CONTINUED) 76
ANXIETY 76
TABLE 11 GLOBAL PIPELINE FOR ANXIETY DISORDER, THROUGH
2015 76
TABLE 11 (CONTINUED) 77
DEMENTIA 77
TABLE 12 GLOBAL PIPELINE FOR ALZHEIMER'S DISEASE,
THROUGH 2015 77
TABLE 12 (CONTINUED) 78
PARKINSON'S DISEASE 79
TABLE 13 GLOBAL PIPELINE FOR PARKINSON'S DISEASE,
THROUGH 2015 79
DEPRESSION 79
TABLE 14 GLOBAL PIPELINE FOR DEPRESSION, THROUGH 2015 80
TABLE 14 (CONTINUED) 81
PERSONALITY/PSYCHIATRIC DISORDERS 81
TABLE 15 GLOBAL PIPELINE FOR OTHER PSYCHIATRIC
DISORDERS, THROUGH 2015 82
TABLE 15 (CONTINUED) 83
SPINAL CORD INJURY 83
TABLE 16 GLOBAL PIPELINE FOR SPINAL CORD INJURY,
THROUGH 2015 83
ADDICTION DISORDERS 83
TABLE 17 GLOBAL PIPELINE FOR ADDICTION DISORDERS,
THROUGH 2015 84
ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) 84
TABLE 18 GLOBAL PIPELINE FOR ATTENTION DEFICIT
HYPERACTIVITY DISORDER, THROUGH 2015 85
SLEEP DISORDERS 85
TABLE 19 GLOBAL PIPELINE FOR SLEEP DISORDERS, THROUGH
2015 85
TABLE 19 (CONTINUED) 86
CHAPTER FOUR: COMPANY PROFILES 87
ABLYNX NV 87
ABLYNX NV (CONTINUED) 88
ADENIOS, INC 89
ALLON THERAPEUTICS, INC 89
ANGIOCHEM INC 90
ANGIOCHEM INC (CONTINUED) 91
ARMAGEN TECHNOLOGIES, INC 92
ARMAGEN TECHNOLOGIES, INC (CONTINUED) 93
BIOASIS TECHNOLOGIES INC 94
BRAINCELLS INC 95
BRISTOL-MYERS SQUIBB 96
CAPSULUTION PHARMA AG 96
CELLIAL TECHNOLOGIES 97
CYPRESS BIOSCIENCES, INC 97
CENERX BIOPHARMA, INC 98
CEPHALON INC 99
COGNITION PHARMACEUTICALS LLC 99
CYTOS BIOTECHNOLOGY AG 100
DIAMEDICA INC 100
DAINIPPON SUMITOMO PHARMA (DSP) CO, LTD 100
ENVIVO PHARMACEUTICALS, INC 101
ELI LILLY AND COMPANY 102
GENZYME 103
FABRE-KRAMER PHARMACEUTICALS, INC 104
GERON CORPORATION 104
GERON CORPORATION (CONTINUED) 105
INSIGHTEC, LTD 106
INTERNATIONAL BRAIN BARRIERS SOCIETY (IBBS) 107
IN CEREBRO 107
JANSSEN PHARMACEUTICA NV 108
H LUNDBECK A/S 108
H LUNDBECK A/S (CONTINUED) 109
TABLE 20 LUNDBECK'S CNS PIPELINE 110
MEDGENESIS THERAPEUTIX, INC (BIOVAIL LAB) 110
MEDIMMUNE 111
MEDINVENT LLC 111
MITHRIDION, INC 112
NEUROGENETIC PHARMACEUTICALS, INC 113
NEUROVIVE PHARMACEUTICAL AB 113
NSGENE A/S 114
NEUREN PHARMACEUTICALS LTD 115
OPTINOSE 115
OTSUKA AMERICA PHARMACEUTICAL, INC 116
PROTHERAGEN, INC 116
PFIZER 117
TABLE 21 PFIZER'S CNS PIPELINE 118
PHARMACO-CELL COMPANY LTD 118
PHARMIDEX 119
RAPTOR PHARMACEUTICAL CORP 120
ROCHE 121
SHIRE PLC 122
SANERON CCEL THERAPEUTICS, INC 123
SOLVO BIOTECHNOLOGY 123
SPENCER PHARMACEUTICAL 124
SOVICELL GMBH 125
SYNAGEVA BIOPHARMA 126
TARGACEPT, INC 127
TETRAGENEX PHARMACEUTICALS, INC 128
TO-BBB TECHNOLOGIES BV 128
TRANSMOLECULAR INC 129
TTY BIOPHARM 130
UCB 131
VECT-HORUS 131
XENOPORT 132
XIGEN SA 133
To order this report:
Pathology Industry: Blood-Brain Barrier Technologies and Global Markets
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article